YH-GKA

structure in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Body Weight (Weight, Body) 01/15/2013 - "In subchronic study with ob/ob mice, YH-GKA showed significant decrease in blood glucose levels and no adverse effects on serum lipids or body weight. " 12/01/2012 - "In a subchronic study with ob/ob mice, YH-GKA showed significant decrease in blood glucose levels and no adverse effects on serum lipids or body weight. "
2.	Type 2 Diabetes Mellitus (MODY) 01/23/2014 - "Therefore, YH-GKA may provide a therapy that compensates for beta cell loss in patients with type 2 diabetes." 12/01/2012 - "Overall, YH-GKA is a promising candidate for the therapy of type 2 diabetes mellitus." 12/01/2012 - "Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus."

1.	Therapeutics